桂林三金(002275.SZ)擬向上海三金增資7500萬元 後者再向寶船生物進行增資
格隆匯 12 月 28日丨桂林三金(002275.SZ)公佈,為進一步滿足全資孫公司寶船生物醫藥科技(上海)有限公司(“寶船生物”)經營發展需要,增強生物板塊研發實力,公司擬使用自有資金向全資子公司上海三金生物科技有限公司(“上海三金”)增資7500萬元,用於上海三金增資全資孫公司寶船生物。此次增資完成後,上海三金註冊資本由5000萬元增加至1.25億元,寶船生物註冊資本由4101.0597萬元增加至11,601.0597萬元。
公司此次使用自用資金對全資子公司增資,全資子公司再對全資孫公司進行增資,是為了滿足孫公司寶船生物的經營發展需要,有利於促進公司研發業務的順利開展與實施,符合公司及全體股東的利益。此次增資系對公司合併報表範圍內的全資子公司和全資孫公司增資,不會對公司的財務狀況和經營成果造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.